Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Author:

Hall Matthew D1,Anderson James M2,Anderson Annaliesa3,Baker David4,Bradner Jay5,Brimacombe Kyle R1,Campbell Elizabeth A6,Corbett Kizzmekia S7,Carter Kara8,Cherry Sara9,Chiang Lillian10,Cihlar Tomas11,de Wit Emmie12ORCID,Denison Mark13,Disney Matthew14,Fletcher Courtney V15,Ford-Scheimer Stephanie L1,Götte Matthias16,Grossman Abigail C1,Hayden Frederick G17,Hazuda Daria J18,Lanteri Charlotte A19,Marston Hilary20,Mesecar Andrew D21,Moore Stephanie22,Nwankwo Jennifer O23,O’Rear Jules24,Painter George25,Singh Saikatendu Kumar26,Schiffer Celia A27,Sheahan Timothy P28,Shi Pei-Yong29,Smyth Hugh D30,Sofia Michael J31,Weetall Marla32,Weller Sandra K33,Whitley Richard22,Fauci Anthony S20,Austin Christopher P1,Collins Francis S2,Conley Anthony J20,Davis Mindy I20

Affiliation:

1. National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA

2. Office of the Director, National Institutes of Health, Bethesda, Maryland, USA

3. Pfizer Vaccine Research and Development, Pfizer, Pearl River, New York, USA

4. University of Washington, Seattle, Washington, USA

5. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA

6. The Rockefeller University, New York, New York, USA

7. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

8. Evotec, Lyon, France

9. University of Pennsylvania, Philadelphia, Pennsylvania, USA

10. Evrys Bio, Doylestown, Pennsylvania, USA

11. Gilead Sciences, Foster City, California, USA

12. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

13. Vanderbilt University, Nashville, Tennessee, USA

14. Scripps Research, Jupiter, Florida, USA

15. University of Nebraska Medical Center, Omaha, Nebraska, USA

16. University of Alberta, Edmonton, Alberta, Canada

17. University of Virginia, Charlottesville, Virginia, USA

18. Merck & Co, Inc, Kenilworth, New Jersey, USA

19. Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

20. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

21. Purdue University, West Lafayette, Indiana, USA

22. University of Alabama at Birmingham, Birmingham, Alabama, USA

23. 1910 Genetics, Inc, Cambridge, Massachusetts, USA

24. US Food and Drug Administration, Silver Spring, Maryland, USA

25. Emory University, Atlanta, Georgia, USA

26. Takeda California, Inc, San Diego, California, USA

27. University of Massachusetts Medical School, Worcester, Massachusetts, USA

28. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA

29. University of Texas Medical Branch, Galveston, Texas, USA

30. University of Texas at Austin, Austin, Texas, USA

31. Arbutus Biopharma, Inc, Warminster, Pennsylvania, USA

32. PTC Therapeutics, Inc, South Plainfield, New Jersey, USA

33. University of Connecticut School of Medicine, Farmington, Connecticut, USA

Abstract

Abstract The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.

Funder

National Institute of Allergy and Infectious Diseases

National Center for Advancing Translational Sciences

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Reference105 articles.

1. Characteristics of SARS-CoV-2 and COVID-19;Hu;Nat Rev Microbiol,2021

2. Molecular targets for antiviral agents;Clercq;J Pharmacol Exp Ther,2001

3. Drug discovery strategies for SARS-CoV-2;Shyr;J Pharmacol Exp Ther,2020

4. Middle East respiratory syndrome;Arabi;N Engl J Med,2017

5. The severe acute respiratory syndrome;Peiris;N Engl J Med,2003

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3